Inspire Medical Systems (INSP) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
20 Mar, 2026Executive summary
Annual meeting scheduled for April 30, 2026, with virtual participation available to shareholders.
Shareholders are encouraged to review proxy materials and vote by April 29, 2026.
Voting matters and shareholder proposals
Election of three Class II directors: Gary L. Ellis, Georgia Melenikiotou, and Dana G. Mead, Jr.
Ratification of Ernst & Young LLP as independent auditor for 2026.
Advisory vote on executive compensation and on the frequency of future say-on-pay votes.
Amendment to phase out classified board structure, moving to annual director elections starting 2029.
Amendment and restatement of the 2018 Incentive Award Plan.
Approval to adjourn the meeting if more time is needed to solicit votes for key proposals.
Board of directors and corporate governance
Proposal to eliminate the classified board structure, transitioning to annual elections for all directors by 2029.
Latest events from Inspire Medical Systems
- Q2 2026 revenue fell 7.6% but gross margin rose; guidance and growth investments increased.INSP
Q2 2026 - Inspire V advances clinical outcomes and reimbursement clarity, supporting growth in sleep apnea care.INSP
Wells Fargo 2026 MedTech Innovation Spotlight - Coding and reimbursement headwinds drive near-term revenue decline, but sequential improvement is expected.INSP
Bank of America Global Healthcare Conference 2026 - Q1 revenue rose 1.6% to $204.6M, but net loss widened and guidance was cut on reimbursement headwinds.INSP
Q1 2026 - All proposals passed amid strong financial growth, leadership updates, and governance reforms.INSP
AGM 2026 - 2025 saw double-digit revenue growth, board declassification plans, and expanded ESG initiatives.INSP
Proxy filing - 2026 guidance: $950M–$1.0B revenue, 4%–10% growth, with reimbursement risks.INSP
Q4 2025 - Q2 2024 revenue up 30% to $195.9M, net income $9.8M, guidance and share repurchase raised.INSP
Q2 2024 - Record 2024 revenue and EPS growth set stage for 17–19% sales increase in 2025.INSP
Q4 2024